Christina Buzis, NP
Primary Care · Yuma, AZNPI 1154894962
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Intuitive Surgical at 46.1% of the total.
Across 44 payments — averaging $58.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Regeneron Healthcare Solutions, Inc.$380
- Lilly USA, LLC$245
- Sanofi-aventis U.S. LLC$136
- Eisai Inc.$122
- ANI Pharmaceuticals, Inc.$108
- plus $395 from 15 others
What the payments were for
- Travel & lodging$1,18446%
- Food & beverage$1,06141%
- Education$32613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $1,184 |
| Regeneron Healthcare Solutions, Inc. | 9 | $380 |
| Lilly USA, LLC | 2 | $245 |
| Sanofi-aventis U.S. LLC | 2 | $136 |
| Eisai Inc. | 6 | $122 |
| ANI Pharmaceuticals, Inc. | 4 | $108 |
| GSK | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| CSL Behring | 1 | $36 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| Tandem Diabetes Care, Inc. | 2 | $33 |
| Merck | 1 | $28 |
| Averitas Pharma Inc. | 1 | $26 |
| AbbVie | 1 | $21 |
| Electromed, Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Biogen | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,165
- MOUNJARO$245
How this compares
$2,571 in reported general payments places this provider in the 85th percentile of 151 primary care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $213,007 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $84,808 |
| Advair HfaFluticasone Propion/Salmeterol | 53 | $34,274 |
| Spiriva RespimatTiotropium Bromide | 40 | $23,598 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $21,498 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 99 | $18,400 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $15,071 |
| Spiriva HandihalerTiotropium Bromide | 14 | $12,434 |
| BreynaBudesonide/Formoterol Fumarate | 47 | $10,941 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $10,660 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 257 | $10,292 |
| Varenicline Tartrate | 36 | $10,271 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $9,996 |
| Tiotropium Bromide | 19 | $9,667 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $42 | $130,173123 claims |
| AstraZenecaBreztri Aerosphere | $16 | $10,66019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 151 primary care providers in Arizona.
Other primary care in Yuma
- Trey PowrzanasPhoenix$16K
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Albert VillafaniaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Lea NickolasAvondale$7K
- Neena VargheseSacaton$6K
- Katy DodtQueen Creek$5K
- Mercy GeorgeQueen Creek$5K
- Charity CorreaPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.